Friday, September 29, 2023


Biotechnology News Magazine

Matica Biotechnology Inc. Breaks Ground on a New 25,000 ft Facility

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

Matica Biotechnology, a contract development and manufacturing organization specializing in the clinical and commercial production of cell and gene therapies, ceremonially broke ground today on its new 25,000 ft2 facility which will house its GMP virus production suites, development laboratories, and company offices.

Matica Biotechnology notes the new building will be located in Providence Park at 2501 Earl Rudder Freeway in College Station.

The groundbreaking ceremony was held Tuesday, February 23 at 10:00 am. College Station Mayor Karl Mooney attended the event, along with members of the College Station City Council, Bryan Mayor Andrew Nelson, Bryan-College Station Chamber of Commerce President/CEO Glen Brewer, Brazos Valley EDC Board Chair Mike Gentry, and Brazos Valley EDC President/CEO Matt Prochaska.

“The global demand for virus products continues to outpace the capacity for production under the stringent Good Manufacturing Practices or GMPs required by regulatory agencies for human use”, stated Matica Bio CEO Dr. Byung Se So. “Our new facility will help to close that gap by establishing  state-of-the-art, modular virus production cleanrooms integrated with the latest vector technologies to maximize speed, flexibility and efficiency throughout our clients’ product development cycle.”

Dr. So continued, “The Brazos Valley area, including College Station, is rapidly becoming one of the most important centers of biotechnology in the country, and it was an easy decision for our company to locate here. The availability of a skilled workforce along with the influence of the Texas A&M University System, will support the level of rapid job growth that we expect throughout the next few years.”

Mr. Timothy Lutz, Matica Bio’s Chief Manufacturing Officer, commented, “Matica Biotechnology is excited to be setting up our operations here in College Station. We look to be active part of our community and are excited to hire a number of local professionals, both for the construction as well as the operational phases. We are planning on utilizing state-of-the-art equipment, processes, and materials to be in a new class of CDMO’s”

“We are honored to welcome Matica Biotechnology to the Brazos Valley as they strive to manufacture solutions for the health challenges of today and tomorrow,” said Brazos Valley Economic Development Corporation President/CEO Matt Prochaska. “A hallmark of our region is its legacy of solving problems facing the world, and Matica Bio’s arrival advances that again. Working with their team in the United States and South Korea has been a pleasure, and we offer the resources and expertise of our community to help them succeed and grow.”

Matica Bio’s GMP facility is scheduled to open in Q3 2021 utilizing a bioreactor-based platform, with access to GMP production slots beginning in early 2022.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine